miR-200c increases the sensitivity of breast cancer cells to Doxorubicin through downregulating MDR1 gene

Antolín, 2015, Circulating miR-200c and miR-141 and outcomes in patients with breast cancer, BMC Cancer, 15, 1, 10.1186/s12885-015-1238-5 Ceppi, 2010, Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non–small cell lung cancer, Mol. Cancer Res., 8, 1207, 10.1158/1541-7786.MCR-10-0052 Chen, 2018, Downregulation of miR-200c-3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2, Oncol. Rep., 40, 3821 Damiano, 2017, Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1, Genes Chromosom. Cancer, 56, 147, 10.1002/gcc.22422 DeSantis, 2019, Breast cancer statistics, 2019, CA Cancer J. Clin., 69, 438, 10.3322/caac.21583 Fisusi, 2019, Drug combinations in breast cancer therapy, Pharm. Nanotechnol., 7, 3, 10.2174/2211738507666190122111224 Ghasabi, 2019, The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration, J. Cell. Physiol., 234, 22581, 10.1002/jcp.28823 Heydari, 2018, The effect of miR-200c inhibition on chemosensitivity (5-FluoroUracil) in colorectal cancer, Pathol. Oncol. Res., 24, 145, 10.1007/s12253-017-0222-6 Hu, 2018, Functional miRNAs in breast cancer drug resistance, Onco. Targets. Ther., 11, 1529, 10.2147/OTT.S152462 Jing, 2015, A feedback regulatory loop involving p53/miR-200 and growth hormone endocrine axis controls embryo size of zebrafish, Sci. Rep., 5, 1, 10.1038/srep15906 Karakatsanis, 2013, Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance, Mol. Carcinog., 52, 297, 10.1002/mc.21864 Kim, 2011, p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2, J. Exp. Med., 208, 875, 10.1084/jem.20110235 Knezevic, 2015, Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential, Oncogene, 34, 5997, 10.1038/onc.2015.48 Kopp, 2012, miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression, PLoS One, 7, 10.1371/journal.pone.0050469 Liu, 2012, miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1, Am. J. Pathol., 181, 1823, 10.1016/j.ajpath.2012.07.009 Liu, 2015, miR-200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment, Pigment Cell Melanoma Res., 28, 431, 10.1111/pcmr.12379 Liu, 2018, miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis, Theranostics, 8, 5801, 10.7150/thno.29380 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method, Methods, 25, 402, 10.1006/meth.2001.1262 Mi, 2018, miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN, Eur. J. Pharmacol., 839, 66, 10.1016/j.ejphar.2018.09.024 Mohammadi, 2016, The role of microRNAs in colorectal cancer, Biomed. Pharmacother., 84, 705, 10.1016/j.biopha.2016.09.099 Mutlu, 2016, miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance, J. Mol. Med., 94, 629, 10.1007/s00109-016-1420-5 Qian, 2010 Rizzo, 2017, Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin, Oncotarget, 8, 71924, 10.18632/oncotarget.18028 Rossi, 2019, Diagnosis and treatment of breast cancer in young women, Curr. Treat. Options in Oncol., 20, 1, 10.1007/s11864-019-0685-7 Schubert, 2011, p53 spreads out further: suppression of EMT and stemness by activating miR-200c expression, Cell Res., 21, 705, 10.1038/cr.2011.62 Seong, 2015, Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer, Breast Cancer Res. Treat., 150, 141, 10.1007/s10549-015-3305-7 Tang, 2013, miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression, Clin. Cancer Res., 19, 5602, 10.1158/1078-0432.CCR-13-1326 Tormo, 2015, MicroRNA profile in response to doxorubicin treatment in breast cancer, J. Cell. Biochem., 116, 2061, 10.1002/jcb.25162 Wu, 2019, miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1, Cancer Gene Ther., 26, 74, 10.1038/s41417-018-0035-0 Yang, 2018, Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis, Mol. Med. Rep., 17, 6211 Zhang, 2019, MiR-200c regulates apoptosis of placental trophoblasts in preeclampsia rats through Wnt/β-catenin signaling pathway, Eur. Rev. Med. Pharmacol. Sci., 23, 7209 Zhang, 2020, LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN, Clin. Exp. Pharmacol. Physiol., 47, 1464, 10.1111/1440-1681.13307 Zhou, 2017, miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1, Biomed. Pharmacother., 85, 113, 10.1016/j.biopha.2016.11.100